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Background: SOX2 is a core component of the transcriptional network responsible for maintaining embryonal
carcinoma cells (ECCs) in a pluripotent, undifferentiated state of self-renewal. As such, SOX2 is an oncogenic
transcription factor and crucial cancer stem cell (CSC) biomarker in embryonal carcinoma and, as more recently
found, in the stem-like cancer cell component of many other malignancies. SOX2 is furthermore a crucial factor in
the maintenance of adult stem cell phenotypes and has additional roles in cell fate determination. The SOX2-linked
microRNA (miRNA) transcriptome and regulome has not yet been fully defined in human pluripotent cells or CSCs.
To improve our understanding of the SOX2-linked miRNA regulatory network as a contribution to the phenotype of
these cell types, we used high-throughput differential miRNA and gene expression analysis combined with existing
genome-wide SOX2 chromatin immunoprecipitation (ChIP) data to map the SOX2 miRNA transcriptome in two
human embryonal carcinoma cell (hECC) lines.
Results: Whole-microRNAome and genome analysis of SOX2-silenced hECCs revealed many miRNAs regulated by
SOX2, including several with highly characterised functions in both cancer and embryonic stem cell (ESC) biology.
We subsequently performed genome-wide differential expression analysis and applied a Monte Carlo simulation
algorithm and target prediction to identify a SOX2-linked miRNA regulome, which was strongly enriched with
epithelial-to-mesenchymal transition (EMT) markers. Additionally, several deregulated miRNAs important to EMT
processes had SOX2 binding sites in their promoter regions.
Conclusion: In ESC-like CSCs, SOX2 regulates a large miRNA network that regulates and interlinks the expression of
crucial genes involved in EMT.
Keywords: SOX2, microRNA, Embryonic stem cell, Embryonal carcinoma, Pluripotency, EMTBackground
SOX2 is a member of the SRY-related HMG-box (SOX)
transcription factor family with a set of well-established
and diverse roles in stem cell potency and maintenance,
embryonic development and cancer [1-10]. It regulates
extensive and often divergent transcriptional networks
across different cell types [1,2,11,12]. SOX2 is best
known as a core pluripotency factor, maintaining the* Correspondence: venckens@tcd.ie; gallagmi@tcd.ie
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is closely co-regulated alongside core pluripotency fac-
tors OCT4 and NANOG in undifferentiated embryonic
stem cells (ESCs), embryonal carcinoma cells (ECCs)
and induced pluripotent stem cells (iPSCs) [8,13,14].
Loss of SOX2 expression in these cell lines triggers their
differentiation. More recently, SOX2 has been identified
as a crucial player in the maintenance and differentiation
of adult stem cells such as in neural stem cells [15]. As
an oncogene, SOX2 has been implicated in many differ-
ent malignancies of the central nervous, gastrointestinal,
circulatory, respiratory, endocrine and skeletal systems,
and also those of the skin, liver, gonads and breastl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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merous tumour types, the suppression of SOX2 has been
reported as a hallmark of gastric carcinoma [16-18]. In
malignancy growing evidence reveals SOX2 to be a cen-
tral regulator of a tumourigenic, stem cell-like subpopu-
lation of tumour cells, frequently referred to as cancer
stem cells (CSCs), which are found to be responsible for
the proliferative and invasive capacities of most tumour
types [7]. Many of the genes regulated by SOX2 in nor-
mal stem cells are aberrantly regulated by this transcrip-
tion factor in cancerous cells with a similar, albeit
malignant phenotype.
MicroRNAs (miRNA) are a functional family of short
(21–23 nt), non-protein coding RNA transcripts that
primarily, but not exclusively, confer regulation of gene
expression by targeting mRNAs for degradation or tran-
sient translational repression by post-transcriptionally
binding these in a directed manner [19]. They are in-
volved in the regulation of almost all cell processes and
maintain cell homeostasis in both healthy and disease
conditions. In cancer and CSCs, many miRNAs have been
identified as tumour suppressive or oncogenic miRNAs
(oncomiRs) [20]. Many of these miRNAs also have im-
portant regulatory functions in pluripotent cells, such as
ESCs and ECCs, and in embryonic development [20,21].
Although the SOX2 transcriptome of protein coding
genes has been previously mapped in various cell types
and tissues, including ECCs, with techniques such as
chromatin immunoprecipitation (ChIP) and gene array
profiling, no extensive SOX2-transcriptome analysis has
been performed for miRNAs in human pluripotent cells
[1,2,11,12,22-25]. Some insight into the SOX2-linked
miRNAome in murine pluripotent cells has previously
been provided by Marson et al. who performed an exten-
sive ChIP-sequencing (ChIP-seq) analysis of SOX2-bound
miRNA promoters in mouse ESCs [26]. Additionally, in a
study of the SOX2 regulatory network in human ESCs
(hESCs), Boyer et al. produced a limited set of exclusively
intragenic miRNAs that were potentially regulated by the
SOX2-binding sites within the promoter regions of their
respective host genes [11]. However, both Marson et al.
and Boyer et al. provide no SOX2 knock-down and
miRNA expression analysis to functionally link this tran-
scription factor to specific miRNAs. Fang et al. profiled
genes and miRNAs regulated by SOX2 in glioblastoma
multiforme (GBM) cells [1]. Notably absent from this
study were an in-depth analysis of miRNAs directly regu-
lated by SOX2 and a large scale combinatorial study of
the gene target regulome of deregulated miRNAs in these
cells.
To map the functions of this miRNA network in pluri-
potent cell and CSC biology, we silenced SOX2 in two
human ECC (hECC) lines followed by a high-throughput
expression analysis of expression changes in its associatedmiRNA network. To reveal genes potentially regulated by
SOX2 through its linked miRNA regulome, we profiled
whole-genome differential mRNA expression and applied
a Monte Carlo algorithm to identify a subset of SOX2-
regulated miRNAs that confer a significant regulatory sig-
nature on the differential gene expression profile in
hECCs. This type of analysis has been performed before
and is enabled by the finding that the majority of total
miRNA-mediated gene suppression functions through
mRNA degradation, thus functional miRNA activity can
be determined by measuring the expression of their tar-
gets at the transcript level [27-36]. Finally, to identify can-
didate miRNAs with a direct transcriptional association to
SOX2, we applied existing SOX2 ChIP-seq and miRNA
promoter data to our differential expression profiles.
To study SOX2 in both a CSC and pluripotent cell
context, we chose the 2102Ep and NTera-2 hECC lines,
the CSC component of teratocarcinoma, a type of germ
cell tumour. The NTera-2 cell line is pluripotent and is
frequently used as cell model to study ectodermal differ-
entiation [37]. 2102Ep cells are considered ‘nullipotent’
as they are resistant to retinoic acid-induced differenti-
ation and form homogenous EC tumours when xeno-
grafted into mice [38,39]. 2102Ep cell differentiation can
however be induced by low-density growth or by silen-
cing core pluripotency factors SOX2 and OCT4 [23,38].
Because 2102Ep and NTera-2 cell lines are phenotypic-
ally similar to hESCs in an undifferentiated state and
during early differentiation stages, they have previously
been used as an alternative hESC model [14,23,38-43].
For this study, 2102Ep and NTera-2 cells could provide
significant insights into the post-transcriptional regula-
tory functions of SOX2 towards both cancer stemness
and embryonic stemness.
Based on parameters set in our analysis we present sev-
eral novel miRNAs that are direct transcriptional targets
of SOX2. Indirect targets of this transcription factor in-
cluded, we found many pro and anti-malignant miRNAs
that also have important functions in embryonic develop-
ment. Statistical analysis of whole-genome differential
mRNA expression revealed a distinct Type 1 epithelial-
to-mesenchymal (EMT) signature in an miRNA/gene
target regulatory network linked to SOX2.
Results
SOX2 knock-down in 2102Ep and NTera-2 cells results in
many altered miRNAs involved in both cancer and
embryonic development
SOX2 was selected for RNAi-mediated silencing in the
two hECC lines and an siRNA with specific complemen-
tarity to SOX2 mRNA (siSOX2). Successful knock-down
was confirmed by comparing SOX2 mRNA and protein
expression with cells transfected with a non-targeting
control (Figure 1A and Figure 1B). SOX2 mRNA was
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Figure 1 Knock-down of SOX2 in 2102Ep and NTera-2 cells. The induced RNAi of SOX2 mRNA by SOX2 siRNA (siSOX2) facilitated a substantial
and significant down-regulation of this gene’s expression in the EC cell lines. (A) As determined by qRT-PCR, very little SOX2 mRNA expression remains
(6.5%) in siSOX2-transfected 2102Ep cells, while the remaining expression in siSOX2-transfected NTera-2 cells is higher (48.5%). SOX2 expression was
compared to that in cells transfected with a scrambled, non-targeting siRNA (NC), which was set at 100%. SOX2 expression was normalised to GAPDH
expression. All experiments were performed in biological triplicate. (B) As determined by Western blot, no SOX2 protein could be detected in the
siSOX2-transfected cells of either cell line when compared to the non-targeting siRNA-transfected controls (NC), vehicle controls (VC) or non-transfected
controls (NTC). GAPDH protein expression was measured to account for equal loading and transfer. (C) RNAi phenotypes of 2102Ep and NTera-2 cells,
four days after SOX2 siRNA transfection. SOX2-silenced EC cells have a flattened, enlarged and more dispersed morphology, compared to SC-transfected
cells, which are, similarly to untreated cells (not shown), small, defined and grown in dense colonies.
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http://www.biomedcentral.com/1471-2164/15/711highly downregulated in 2102Ep cells, while in NTera-2
cells 49% reduced mRNA expression was reported.
However, subsequent protein analysis showed that the
SOX2 protein expression was completely eliminated,
confirming successful knock-down.
As shown in Figure 1C, distinct changes in cell mor-
phology were recorded in 2102Ep and NTera-2 cells
three days after siSOX2 transfection compared to cells
transfected with a non-targeting siRNA control. For bothcell lines, the cells had a flatter and larger appearance.
They were also more evenly dispersed in monolayers,
which differed from their normal, undifferentiated phe-
notype as densely packed colonies. This phenotypic
change is characteristic of ECC differentiation.
We profiled miRNA expression using high-throughput
quantitative real-time PCR (qRT-PCR) arrays in 2102Ep
and NTera-2 cells three days after transfecting them
with siSOX2 or a non-targeting, scrambled siRNA
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validated miRNAs, covering the majority of the Sanger
miRBase v14 miRNA database [44]. From this set of
miRNAs, 99 and 62 miRNAs were significantly (P ≤
0.05) deregulated in 2102Ep and NTera-2 cells respect-
ively (Figure 2 and Additional file 1: Table S1). These in-
clude the minor strand (star, ‘*’) miRNAs, which have
increasingly been attributed with biological functions.
The large majority of differentially expressed miRNA in
both cell lines were downregulated, suggesting that
SOX2 is predominantly a transcriptional activator of
miRNAs in hECCs.
14 miRNAs were mutually deregulated (mir-1180,
−125b, −135b*, −138, −19a, −221, −31, −31*, −372, −375,
−378, −455-3p, −517c, −522), of which four were mutually
deregulated by over 2-fold each (miR-135b*, −138, −375,
−522). Another four miRNAs were oppositely regulated
(miR-1197, −miR-181a-2*, −184, −218), with miR-181a-2*
showing a large difference between 2102Ep (up) and
NTera-2 cells (down). These results will be further de-
tailed in following paragraphs.-5
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Figure 2 Differential expression of miRNA in 2102Ep and NTera-2 cell
(P≤ 0.05) deregulated miRNA three days after SOX2 knock-down in 2102Ep (A
in cells transfected with a non-targeting control. 99 and 62 miRNAs were dere
substantial bias towards miRNA downregulation after the knock-down of SOX
biological replicates. Blue markers indicate miRNAs that form an autoregulato
master regulators of differential gene expression in hECCs. Red markers indica
this study.Many deregulated miRNAs in 2102Ep and NTera-2
cells after SOX2 knock-down have previously reported
oncogenic or tumour suppressive functions. In addition,
many are actors in the maintenance of stem cell pheno-
types or guide embryonic development and differentiation.
We cross-analysed the deregulated miRNAs in both hECC
lines with hESC miRNA data from Stadler et al. and the
miRCancer database, a curated repository of oncomiRs
and tumour suppressor miRNA [45,46]. Table 1 contains
a summary of deregulated miRNAs that have roles in can-
cer and also are enriched in hESCs or are differentially
expressed during early hESC differentiation. This demon-
strates great overlap of the deregulated miRNAs in our
dataset and many miRNAs involved in cancer and stem
cell biology.
We also compared the miRNA profiles of the 2102Ep
and NTera-2 cell lines in their native, undifferentiated
state. This comparison produced 213 differentially regu-
lated miRNA when both datasets are normalised to their
respective global mean miRNA expression (Additional
file 2: Table S2). This substantial difference in miRNA7 1*
4 9 5p 4 7 a 2 a 7 3
 2 4 8
p
2
lines after induced SOX2 silencing. Total number of all significantly
) and NTera-2 cells (B) normalised to the respective miRNA expression
gulated in 2102Ep and NTera-2 cells respectively. Both charts visualise a
2. These charts represent the mean expression values across three
ry loop with SOX2. Black markers indicate miRNAs found to be significant
te miRNAs with SOX2 binding sites in their promoters as found in
Table 1 Deregulated oncogenic or tumour suppressive miRNAs in 2102Ep and NTera-2 cells with an upregulated or
downregulated profile in undifferentiated or differentiated hESC data from Stadler et al. [45]
2102Ep hESC undifferentiated hESC differentiated
OncomiR Downregulated miR-519c Upregulated Downregualted
miR-19a miR-519d miR-24 miR-26a
miR-512-5p miR-520a* miR-31
miR-517a miR-520b miR-125b
miR-517b miR-520f mir-182
miR-517c miR-520 g miR-221
miR-518b miR-520 h
miR-518f
miR-525
Tumour Suppressor miRNA Downregulated Upregulated Downregulated
miR-148a miR-424 miR-26a
miR-27b miR-31
miR-28 miR-125b
miR-30d
miR-149
miR-331
NTera-2 hESC undifferentiated hESC differentiated
OncomiR Downregulated Upregulated Downregulated
miR-18a miR-193b miR-22
miR-19a miR-125b
miR-19b miR-221
miR-367 miR-222
miR-374
miR-517c
Tumour Suppressor miRNA Upregulated Downregulated
miR-145 miR-22
miR-193b miR-31
miR-125b
miR-34c
The individual titles ‘Downregulated’ and ‘Upregulated’ indicate the differential expression of each miRNA after SOX2 knock-down in either 2102Ep or NTera-2 cell
lines or both.
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http://www.biomedcentral.com/1471-2164/15/711expression profiles could contribute to the divergence of
differential miRNA expression profiles in 2102Ep and
NTera-2 cells after SOX2 knock-down.
Statistical identification of an enriched miRNA regulatory
signature reveals the regulation of EMT-related genes
Current research has primarily focused on the direct ac-
tion of SOX2 on its transcriptional target genes in the
context of pluripotency, differentiation and cancer. To
expand the picture of SOX2 regulation beyond this,
we intended to identify SOX2-linked miRNAs that
conferred a significant regulatory signature on the dif-
ferential gene expression profile in hECCs after SOX2
knock-down.For this approach, genome-wide gene expression ar-
rays were used to generate differential gene expression
profiles of the 2102Ep and NTera-2 cells from the same
SOX2 knock-down samples used for miRNA profiling
analysed against the same non-targeting control samples.
All genes that were significantly ≥2-fold up or downreg-
ulated were included in further analysis and can be
found in Additional file 3: Table S3. Using a Monte
Carlo simulation algorithm combined with the miRNA
target-prediction software, TargetScan 6.0, we analysed
the gene expression data to identify deregulated miRNAs
that target significantly more of the oppositely deregu-
lated genes than would be expected by chance. This stat-
istical method has previously been successfully applied
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one-carbon metabolism-linked genes and lipid metabol-
ism genes [47,48].
Whole-genome profiling revealed the deregulation of
402 genes in 2102Ep cells and 131 genes in NTera-2
cells, with 54 commonly deregulated genes between the
two cell lines (Figure 3A and Additional file 3: Table S3).
Gene ontology analysis revealed, particularly in 2102Ep
cells, the deregulation of many markers of embryonic
development, early tissue morphogenesis, cell differenti-
ation and respective pathways involved, such as the Wnt
pathway (Additional file 4: Table S4) [49]. An expected
feature was the upregulation of 26 functional markers of
mesodermal differentiation and EMT (see Figure 3B),
with the exception of NRP1 in NTera-2 cells, which was
downregulated in this cell line, but upregulated in
2102Ep cells. Previous evidence demonstrates the induc-
tion of EMT and the acquisition of neural crest cell
traits in hESCs after SOX2 knock down and the central
roles of SOX2 in this type of cell fate determination haveFigure 3 EMT-specific miRNA-target relationships directly and indirec
diagram displays the exclusive and mutual expression of all ≥2-fold up or dow
Excluded from the mutual group were the four oppositely deregulated genes
significantly more genes were deregulated in 2102Ep cells than NTera-2 cells. (
expressed in 2102Ep and NTera-2 cells combined. Those denoted in red are ta
these were previously validated. Together with SOX2 these miRNAs and target
compiled from predicted miRNA and gene interaction data from this study an
validated functional relationships, which include those predicted by this study,
Red arrows represent transcriptional control by SOX2. Stripes without arrowhea
SOX2 of genes that could be transcriptionally inhibited by SOX2 in our study. S
ZEB2 as per the ChIP data from Lister et al. and Boyer et al. [11,12].been previously suggested [22,50]. This phenotypic
change is particularly evident in 2102Ep cells, which
produced more altered markers than NTera-2 cells. In
cancer, EMT is a process of transdifferentiation by
which epithelial cells lose their cell-cell adhesion and
adopt a migratory mesenchymal phenotype enabling
them to metastasise to other tissues. Unexpectedly,
some established EMT inhibitors were upregulated in
NTera-2 (CDH1/E-cadherin) and 2102Ep cells (KRT19
and HAS2) [51,52]. This observation will be further
touched upon in the Discussion section. Among the 26
EMT markers, SNAI2/Slug and CDH2/N-cadherin have
been previously shown to be transcriptionally activated
by SOX2 during Type 3 and Type 1 EMT respectively.
In our data, these genes are upregulated after SOX2
knock-down, suggesting an opposite transcriptional rela-
tion to SOX2 [10,53]. On the other hand, T/Brachyury
and EOMES were previously found to be repressed by
SOX2 in Type 1 EMT, which is in concordance with our
findings [54,55].tly regulated by SOX2 in 2102Ep and NTera-2 cells. (A) This Venn
nregulated genes in 2102Ep and NTera-2 cells after SOX2 knock-down.
. As shown, despite a large overlap between the two cell lines,
B) This chart displays the expression levels of all 26 EMT genes differentially
rgets of the 11 miRNAs in Table 2 as predicted by our analysis. Several of
s form a complex network of EMT regulation (C). The EMT network
d previously established interactions. The thick arrows represent previously
while the thin arrows are novel relationships predicted by this study alone.
ds or bars represent the previously validated transcriptional activation by
OX2 binding sites were also found in the promoter regions of HAS2 and
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and NTera-2 differential gene expression datasets and
cross-referencing with the results with the differential
miRNA expression results revealed 10 miRNAs in
2102Ep cells (mir-26a, miR-28, miR-30c, miR-148a, miR-
200b, miR-517b, miR-518a-3p, miR-518b, miR-518c,
miR-518f ) and two miRNAs in NTera-2 cells (miR-200c
and miR-367) to be potential master regulators of their
inversely regulated target genes. Certain human miRNA
families are broadly conserved across many vertebrate
species, while the evolutionary conservation of others is
limited to mammals or mammalian species of close
common ancestry. The corollary is that poorly con-
served miRNAs may bind to poorly conserved target
sites. To maximise the probability of identifying true
miRNA targets we limited our scope to target sites of
equal conservation to their respective miRNAs. While
miR-26a, miR-30c, miR-148a, miR-200b, miR-200c and
miR-367 are broadly conserved across vertebrate spe-
cies, miR-28 is conserved only in mammals and miR-517b,
miR-518f, miR-518b, miR-518c, miR-518a-3p, all as
members of the C19MC polycistron, are found only
in primates.
To identify high-probability gene targets we further fil-
tered the results by microT-CDS and miRanda (August
2010 release) cross-analysis and removed any targets
that were not predicted by either of these tools (2 cases)
[56,57]. The results are found in Table 2 and with the
added prediction scores in Additional file 5: Table S5.Table 2 Significantly represented miRNAs in 2102Ep and NTe
Cell line miRNA Fold change Targets
2102Ep
miR-148a −3.63 ARRDC3
ITGA5 [5
mir-26a −1.73 ADAM19
HOXA5
NRIP1, P
miR-200b −1.48 AHNAK, A
GATA2
NRP2, NT
miR-30c −1.23 ACTC1, A
FAM123B
PRTG, RA
miR-28 1.71 DPF1 , IQ
miR-517b −1.94 CACNG4,
miR-518a-3p −2.47 FRAS1, IL
miR-518b −2.06
miR-518c −3.33
miR-518f −1.87
NTera-2
miR-200c −1.80 AHNAK,
miR-367 −1.46 ATP2B4,
Genes in bold are previously confirmed targets of their respective miRNAs which al
and either microT-CDS or miRanda (August 2010 Release). All other genes were preThe results reveal a combined set of 128 miRNA-target
interactions with 85 unique genes potentially regulated by
our significant set of miRNAs. Of these, 99 miRNA-target
interactions are predicted by all three target prediction
tools used in this study governing a high-confidence set of
75 unique genes, 19 of which have two or more high-
confidence miRNA interactions. This portrays a dense
network of interlinking miRNA-target regulation contain-
ing many previously validated miRNA targets (expressed
in bold in Table 2) and many potentially new targets.
Many genes related to EMT pathways were found to be
regulated by several differentially expressed miRNAs. Of
these, members of the miR-200 family have been the most
extensively studied in this context [72]. We discovered
that a group of 11 miRNAs in Table 2, all of which were
downregulated, could target 14 differentially expressed
EMT-related genes from both cell lines combined. Four of
these miRNAs, miR-200b, miR-200, miR-30c and miR-
148a, are established inhibitors of EMT and metastasis by
targeting ZEB1 and ZEB2 (miR-200b/200c), TWF1 and
VIM (miR-30c) and mesenchymal-to-epithelial transition
(MET) (miR-148a) [68,73,74]. Additionally, miR-26a has
targets that were verified in non-EMT studies, but which
have independently established functions in EMT and me-
tastasis. These include HMGA2 and LEF1 (miR-26a)
[60,62,75]. Figure 3C illustrates a network of validated and
novel SOX2-miRNA-target interactions found in this
study. Some of these interactions are further detailed in
the Discussion section.ra-2 data with their associated targets
[58], ATP2B4, CHD7, ELMO1, FAM123B, H2AFY, HDGF, HMGA2, IL6ST,
9], ITGB8 [59], LIX1, NRP1, PREX1, TEAD1, TMEM54
, AMOT, CDH2, CDH11, CSNK1G1, ENC1, ENPEP, HAS2, HMGA2 [60],
[61], HOXA9, LHX1, ITGA5, ITGB8, LEF1 [62], LIFR, MAP2 [63], NID1,
LXNA2, PRTG, SSFA2, TFAP2A, USP3, WNT5A, ZSWIM6
RRDC3, CDH11, CNKSR3, CNTFR, EFNA1 [64], EMP1, FN1 [65],
[66], GLI3, HEG1, HOXA5, KIAA0101, MAP2, MBNL3, NKD1, NRIP1,
F3, PLXNA2, PRTG, ST6GALNAC5, TEAD1, TFAP2A [67], WWC3, ZEB2 [68]
DAM19, ADAMTS9, AHNAK, CAMK2N1, CHD7, CSNK1G1, CYP24A1, ELMO1,
, GRHL2, ITGA5, KIAA1024, LHX1, LIFR, MBNL3, NID1, NRIP1, NRP2, PLXNA2,
RG, RASGRP3, RHOB, SNAI1 [69], SNAI2, TBL1X, TEAD1, TIMP3, ZEB2, ZSWIM6
SEC2, PRUNE2
HOXA5, NKD1, PRTG, ZEB2, ZNF436
13RA1, TEAD1, TGFBR3
CITED2, MBNL3, NTF3 [70], PLXNA2, PRTG, SEMA6D [71], YPEL2
CADM2, EOMES, HAND1, MBNL3, PKDCC, SEMA6D, SESN3
so showed up in our data. Genes in cursive style are predicted by TargetScan
dicted by all three prediction tools.
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promoter regions
To provide further insight into the miRNA transcrip-
tome under direct control by SOX2, we cross-analysed
our profiling data with existing genome-wide SOX2
ChIP data.
We first performed a meta-analysis of SOX2 transcrip-
tion factor binding sites (TFBSs) in proximity of miRNA
transcription start sites (TSSs). At the time of this study,
no previously published SOX2 ChIP experiments were
performed for hECC lines. Because of this we adopted a
similar strategy used by Greber et al. and performed
analysis with SOX2 ChIP data from hESCs as a substi-
tute [23]. The assumption that SOX2 binds similar gen-
omic loci in both hECCs and hESCs was based on the
evidence supporting a phenotypic similarity between
these cell types and further supported by functional
studies which show that SOX2 has highly comparable
roles in the maintenance and differentiation of these cell
lines [23,76]. Some differences do exist between hECC
and hESCs on the genetic and transcriptomic level, but
current research accepts that this is limited to the ex-
pression and alternative splicing of only a relatively small
number of genes [77].Table 3 MiRNAs with SOX2-binding sites in hESCs which were
Precursor Mature miRNA Fold-change Distan
2102Ep
hsa-mir-9-2 miR-9* 5.16
hsa-mir-9-2 miR-9 3.83
hsa-mir-181a-2 miR-181a-2* 3.05
hsa-mir-424 miR-424 2.87
hsa-mir-301a miR-301 1.78
hsa-mir-182 miR-182 −2.08
hsa-mir-942 miR-942 −2.10
hsa-mir-183 miR-183* −2.32
hsa-mir-183 miR-183 −2.90
hsa-mir-135b miR-135b* −3.04
hsa-mir-766 miR-766 −5.04
NTera-2
hsa-mir-19b-2 miR-19b −1.35
hsa-mir-22 miR-22 −1.58
hsa-mir-324 miR-324-5p −1.91
hsa-mir-124-2 miR-124 −1.98
hsa-mir-22 miR-22* −2.02
hsa-mir-7-1/7-3 miR-7 −2.27
hsa-mir-135b miR-135b* −2.33
hsa-mir-135b miR-135b −2.56
hsa-mir-181a-2 miR-181a −2.61
hsa-mir-577 miR-577 −3.31
hsa-mir-181a-2 miR-181a-2* −4.47
hsa-mir-1251 miR-1251 −7.90Two whole-genome hESC SOX2 ChIP datasets were
included in the analysis; those previously published by
Boyer et al., and Lister et al. [11,12]. Lister et al. per-
formed ChIP-Seq of the whole genome, while Boyer
et al. used a more limited ChIP-on-chip based method
which covered the -8 kb to +2 kb genomic regions rela-
tive to transcription start sites of 17,917 annotated
genes.
Secondly, we compiled a list of TSSs from two re-
sources: a dataset of miRNA TSSs identified by Bulik-
Sullivan et al. and all host gene and miRNA TSSs from
the miRStart database [78,79]. All miRNAs with SOX2
binding sites 5 kb upstream or downstream from their
miRNA TSS and, where applicable, their host gene TSS,
were compiled and included in further analysis.
In total, 71 unique miRNA precursors were found to
have one or more SOX2 binding sites (see Additional file
6: Table S6). We compared this set of miRNAs with all
miRNAs that we found to be significantly down or up-
regulated in the 2102Ep and NTera-2 cell lines. From
this analysis, 11 deregulated mature miRNAs in 2102Ep
cells and 12 in NTera-2 cells were found to have prox-
imal SOX2 binding sites as shown in Table 3. In NTera-
2 cells, all these miRNAs were downregulated, while inderegulated in 2102Ep and NTera-2 cells
ce to TSS Expression EMT/MET Validated targets × hECC data
1887
1887 Up in EMT [80] CDX2, ID2
−467
3042 Up in EMT [81]
55
−4286 Up in MET [82] RARG, SNAI2
−126
−4286
−4286 Down in EMT [83] SNAI2
4448
−1234
−932 PRUNE2
−186 Up in EMT [84]
−2058 AHNAK
−5 Down in EMT [85]
−186
−2262 Down in EMT [86]
4448
4448
−467 Up in EMT [87] NANOG
1455
−467
1717
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Only miR-135b* and miR-181a-2* were commonly listed
for both 2102Ep and NTera-2 cells. This signifies a dif-
ference between the two hECC lines in response to
SOX2 downregulation.
None of the miRNAs listed in Table 3 have been vali-
dated before as transcriptional targets of SOX2, reveal-
ing a novel network of miRNAs potentially directly
regulated by SOX2 in pluripotent cells. In general, few
miRNAs have so far been identified as direct transcrip-
tional targets of SOX2 in human cells. Previous research
efforts have focused on its regulation of the ESC-specific
miR-302-367 cluster and recently SOX2 has been impli-
cated in a direct negative feedback loop with the miR-
200 family [88-90]. Despite the significant deregulation
of miR-302c and miR-200b in 2102Ep cells and miR-
200c and miR-367 in NTera-2 cells, none of these miR-
NAs were identified as SOX2 transcriptional targets in
our data. The false negative result for the miR-302-367
cluster can be explained by the absence of identifiable
TSSs for this cluster. However, two SOX2 binding sites
were found in a <2000 bp proximity of the miRNA pre-
cursors, confirming previous reports. No SOX2 binding
sites were in proximity to the TSSs of miR-200b and
miR-200c as mapped by Boyer et al. and Lister et al.
A literature search revealed a substantial overlap of
miRNAs potentially controlled by SOX2 as listed in
Table 3 and miRNAs functionally linked to EMT or its
counterpart, MET, in cancer or embryonic stem cell
lines. Table 3 column ‘Expression during EMT/MET’ in-
dicates the direction of differential expression during
EMT or MET. With the exception of miR-22 and miR-
181a in NTera-2 cells, the differential expression of all
miRNAs listed in Table 3 correspond with their reported
expression during EMT or MET.
Additionally, with the aid of miRTarBase, a repository
of validated miRNA-target interactions, genes deregu-
lated in 2102Ep and NTera-2 cells after SOX2 knock-
down were included as previously validated targets [91].
Only interactions validated with strong evidence (reporter
assay, Western blot or qPCR) were included. Notably,
SNAI2/Slug, an important EMT gene, is upregulated in
2102Ep cells, while its previously validated miRNAs, miR-
182 and miR-183, are downregulated. Both miRNA are
members of the same miR-183-96-182 cluster in the gen-
ome. This potentially presents alternative route through
which SOX2 controls SNAI2/Slug transcription (Figure 3C).
Discussion
SOX2 is a major pluripotency marker and oncogene. Al-
though previous studies have addressed the SOX2 tran-
scriptional profile of protein-coding genes in both
hESCs and hECCs [11,12,23], no study has yet profiled
the SOX2 miRNA profile in human pluripotent cells.Successful previous attempts have mapped the direct
transcriptional miRNA network of SOX2 in mouse ESCs
and human GBM, but no integrated differential gene
and miRNA expression analysis was performed and none
exist in human pluripotent stem cells [1,26]. The basis
of this study was to attempt such analysis and to provide
a platform for future SOX2 and pluripotency-linked
miRNA-target discovery and validation.
ECCs have been previously used as a model to study
cancer stemness, ESCs and embryonic development
[37,38,40,42,77,92]. As CSCs of embryonal carcinoma
and teratocarcinoma, they have been subjects of cancer
stemness studies, while their phenotypical similarities
with ESCs have kept ECCs interesting to researchers
who study embryonic development and ESC biology. Re-
cently, these fields have converged in research which uti-
lises ECCs as a model to investigate ESC and iPSC
tumourgenicity and cancer cells expressing embryonic
biomarkers [42,77,93].
MiRNA profiling after SOX2 knock-down reveals a distinct
phenotypes in 2102Ep and NTera-2 cells
We profiled the differential expression of 754 miRNAs in
two SOX2 knock-down ECC lines. To our best know-
ledge, this is the first study to map a SOX2-linked miRNA
network by a high-throughput method in human pluripo-
tent cell lines. MiRNA profiling revealed the significant
deregulation 99 and 62 unique mature miRNAs in 2102Ep
and NTera-2 cells, of which only 18 were common be-
tween these groups, with four miRNAs of this subset op-
positely deregulated. The large difference in miRNA
response to SOX2 knock-down signifies the phenotypic
differences between the 2102Ep and NTera-2 cell lines
which is further supported by the different miRNA pro-
files between undifferentiated 2102EP and NTera-2 cells.
However, the miRNA profiles in both cell lines showed
certain features expected in hESCs after SOX2 silencing.
In 2102Ep cells, several ESC-specific miRNAs were down-
regulated, most notably 28 members of the C19MC poly-
cistron. In NTera-2 cells, this cluster is expressed, but
only two of its miRNAs (miR-517c and miR-522) were
downregulated. C19MC is located on chromosome
19q13.42 and conserved to primates only. In normal tis-
sue, its miRNAs are specifically expressed in ESCs, ECCs
and placental tissue. Although the precise function of
C19MC is still quite elusive, its expression is rapidly lost
during early ESC differentiation [94]. However, C19MC
re-expresses in several cancer types and in particular em-
bryonal brain tumours in which it activates an early devel-
opmental program by driving global methylation changes
[95]. The downregulation of C19MC after SOX2 knock-
down in 2102Ep cells and its its apparent resistance to this
in NTera-2 cells aligns the phenotype of the former cell
line closer to that of hESC differentiation than the latter.
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autoregulatory network of core pluripotency factors
The differential expression of three miRNAs, miR-9*,
miR-145 and miR-126, which have previously been vali-
dated to target SOX2, suggests the possible existence of
novel autoregulatory loops between SOX2 and miRNAs
it directly or indirectly regulates. MiR-9*, which is up-
regulated in 2102Ep (Figure 2A), and miR-145 and miR-
126, which are upregulated and downregulated in
NTera-2 respectively (Figure 2B), all have been validated
to repress SOX2 [18,96-98]. While the downregulation
of miR-126 points towards a negative feedback mechan-
ism, the upregulation of miR-9*, which has a proximal
SOX2 binding site in its promoter region (Table 3), and
miR-145 indicates the existence of positive feedback
loops. In fact, Fang et al., who found similar deregula-
tion of miR-145 upon the knock down of SOX2 in GBM
cells, proposed this association [1].
Expanding these autoregulatory networks beyond the
direct targeting of SOX2 reveals additional regulatory
connections between SOX2-targeted miRNAs (Table 3)
and regulators of SOX2 expression. The pluripotency
factor NANOG reciprocally induces SOX2 expression
and both can cooperatively enhance their own expres-
sion in stem cells, including ESCs, ECCs and CSCs
[99,100]. As expected, NANOG was similarly downregu-
lated in both ECC lines in this study. In hematopoietic
stem cells, miR-181a-2*, a member of the miR-181 fam-
ily and deregulated in both 2102Ep and NTera-2 cells,
can directly target NANOG [101]. The expression of the
miR-181 family increases during early hESC differenti-
ation and has previously been identified as regulators of
stem cell differentiation, including that of hESCs and
CSCs [102-105]. We found that the miR-181a/-2a* pre-
cursor contains a SOX2 binding site in close proximity
to its TSS (Table 3), suggesting its direct regulation of
these miRNAs. MiR-181a-2* was upregulated in 2102Ep
cells, while its complement strand miR-181a was simi-
larly upregulated just outside the minimal threshold of
statistical significance (not shown). If miR-181a-2* tar-
gets NANOG during 2102Ep differentiation, this would
present an alternative mechanism of NANOG regula-
tion by SOX2 in this ECC line, and possibly other cell
lines.
Integrated analysis reveals a distinct EMT miRNA-target
regulatory network
From a statistical cross-analysis of miRNA and gene pro-
filing data we identified 12 miRNAs that controlled a
combined set of 85 deregulated genes, of which 75 were
predicted by three computational target prediction tools.
This set was enriched with a subgroup of 17 genes in-
volved in EMT (Figure 3C). SOX2 has recently been dir-
ectly linked to EMT and metastasis in cancer, and as anoncogene is considered to be a promoter of EMT during
disease progression [3,106-108]. Although the precise
mechanisms by which SOX2 contributes are still quite
elusive, its cancer stem cell regulatory and EMT func-
tions probably overlap. So far, one study found that its
transcriptional regulation of the Wnt/β-catenin pathway
was a contributing factor [108]. Recent evidence sug-
gests that EMT could attribute to the generation of
CSCs, possibly further implicating SOX2 in a network of
tumorigenesis and progression though its expression in
a cancer cell subpopulation [109,110].
From our results we present an expanded network of
miRNA interactions, directly and indirectly regulated by
SOX2, that could govern EMT during embryonic devel-
opment and in CSCs. The significant representation of
known and putative miRNA inhibitors of EMT with vali-
dated EMT targets (miR-200b, miR-200c, miR-30c, miR-
148a and miR-26a) provides functional significance to
the wider SOX2-regulated miRNA-target network re-
vealed in this study. Furthermore, independent from the
statistical target analysis, miR-9/9*, a highly charac-
terised promoter of EMT and upregulated in 2102Ep
cells, has a SOX2-binding site in its promoter region
(Table 3), further revealing a SOX2-linked miRNA EMT
network [80].
This network includes highly characterised mesenchy-
mal markers such as ZEB2, LEF1, FN1 (fibronectin),
CDH2 (N-cadherin), SNAI1 (Snail) and SNAI2 (Slug).
Nearly all genes in this upregulated group of genes are
promoters or effectors of EMT. The exception is CDH1/
E-cadherin in NTera-2 cells, which normally downregu-
lates during EMT, while it is upregulated in our dataset.
The latter cannot be fully explained without further ex-
perimentation. Overall, the results demonstrate a miRNA
link between SOX2 and EMT-related genes in 2102Ep
cells. In a recent study, Cimadamore et al. demonstrate
that the differentiation of hESCs to sensory neurons rely
on a transient up- and downregulation of SOX2 expres-
sion [22]. SOX2 expression reduces during the initial dif-
ferentiation and EMT of hESCs to neural crest cells after
which SOX2 is re-expressed during the differentiation of
these cells towards neuronal progenitors. The induction of
EMTgenes in 2102Ep cells represent the first phase of this
differentiation program and the detailed network of
miRNA-target interactions we present in our study could
assist this process. Furthermore, despite their pluripo-
tency, NTera-2 cells appear have a limited capacity of
undergoing this transformation or perhaps represent a
more progressed phenotype along this differentiation pro-
gram as suggested by the upregulation of CDH1/E-cad-
herin and the downregulation of NRP1. The induction of
a combined gene and miRNA EMT programme by SOX2
knock-down in 2102Ep cells suggest the activation of a
form of Type 1 EMT.
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function to validated EMT miRNAs
The characterisation of a miRNAs with SOX2 binding
sites in their promoter region yielded a subset of deregu-
lated miRNAs in 2102Ep and NTera-2 that are highly
probable to be transcriptionally regulated by SOX2. 9
miRNAs have been previously validated as functional ac-
tivators or inhibitors of EMT or MET. In 2102Ep cells,
inhibitors of EMT, miR-9 and miR-424, and an activator
of MET, miR-182, are all upregulated. Conversely, an in-
hibitor of EMT, miR-183, is downregulated. This further
supports the hypothesis of SOX2 as a regulator and an
inhibitor of Type 1 EMT in 2102Ep cells. In NTera-2
cells, miR-124-3p, miR-7, miR-22 and miR-181a are
downregulated. However, only miR-124-3p and miR-7
are inhibitors of EMT, while miR-22 and miR-181a are
activators. As indicated by the differential expression of
certain genes in NTera-2 cells, this could be representa-
tive of a more progressed phenotype. This has been sug-
gested before, for despite their pluripotent nature,
NTera-2 cells appear to be intrinsically primed towards
neural differentiation, a process also governed by SOX2
[22,111,112]. Unbiased screening of the miRNAs in
Table 3 with validated targets from miRTarBase yielded
only few genes that were deregulated in 2102Ep and
NTera-2 cells. It is possible that functional response of
targets of these miRNAs is delayed or that these miRNAs
confer their functionality through translational repres-
sion. Furthermore, curated databases such as miRTarBase
only represent a fraction of the results in the literature
and, as such, several validated targets may been missed.
A direct association between master regulator miR-
NAs (Table 2) and miRNAs with SOX2 binding sites in
their promoter regions (Table 3) could not be found.
This may be due to the high stringency of statistical ap-
proach to identifying master regulator miRNAs taken in
this study rather than an alternative SOX2 binding pro-
file to miRNA promoter regions. Despite this, the master
regulators, miR-200b, miR-200c and miR-367, have been
previously established transcriptional targets of SOX2,
indicating that this transcription factor could have a
large influence on the targets of these miRNAs through
their genomic regulation [88-90].
Conclusion
In this study we profiled the SOX2-linked miRNAome
and its associated regulatory network in pluripotent and
nullipotent cancer stem cells. The findings add to a
growing body of results that map the cell and context
specific multifunctionality of SOX2 in the maintenance
and direction of stem cell phenotypes. The results pre-
sented in this study suggest a miRNA link between
SOX2 and Type 1 EMT markers in the 2102Ep ECC
line. The apparent role of SOX2 as an inhibitor of EMTduring embryonic development is opposite of its role as
a promoter EMT in metastatic neoplasms, even though
many of the same miRNAs are involved. Future research
could further and individually validate the presented
miRNAs and targets in relation to SOX2-linked EMT,
embryonic development and cancer.
Methods
Cell culture and functional transfections
For this study we compared two hECC lines; 2102Ep
and NTera-2 (kind gifts from Prof. Peter Andrews, Uni-
versity of Sheffield). These cell lines have a high turn-
over and remain in an undifferentiated state at high
density. The cells were grown in growth medium contain-
ing high-glucose DMEM supplemented with 10% FCS and
2% penicillin-streptomycin (Lonza, Switzerland). For ex-
perimentation, six-well plates were seeded 24 hours prior
to oligonucleotide transfection in growth medium without
antibiotics. This study did not involve human samples or
data and as such did not require ethical approval.
SOX2 knock-down was performed with a pre-designed
Silencer® Select siRNA (s13295, Life Technologies, USA)
with a sense sequence of AGUGGAAACUUUUGUCG
GATT and an anti-sense sequence of UCCGACAAAA
GUUUCCACUCG. In NTera-2 cells, functional trans-
fections were performed as per manufacturers’ protocols
with 30 nM siRNA and Lipofectamine® RNAiMAX® (Life
Technologies, USA). For 2102Ep cells, 15 nM siRNA with
Lipofectamine ® 2000 (Life Technologies, USA) was suffi-
cient. As a negative control, samples transfected with
the non-targeting siRNA, Silencer® Select Negative Con-
trol #1 were included. Vehicle controls, absent of any
siRNA, and non-transfected controls, absent of any
transfection agent or siRNA, were also included to test
the effects of the transfection components. The cells
were forward transfected in a serum-free medium con-
taining Opti-MEM® I, transfection agent and siRNA for
6 hours at 37°C. The medium was replaced with normal
growth medium and the cells were incubated in appro-
priate conditions for 72 hours with a daily medium re-
fresh after which the cells were harvested for Western
blot and RNA expression analysis.
Validation of SOX2 knock-down
Successful knock down of SOX2 by siRNA was assessed
by measuring relative mRNA and protein levels with
qRT-PCR and Western blot respectively. Briefly, total
RNA and protein samples were isolated and purified
from the cells using the miRVANA® PARIS system
(Ambion, USA). MRNA expression was determined
using the the TaqMan® qRT-PCR system (Applied Bio-
systems, USA) as per manufacturer’s protocols. Relative
quantification with the 2-ΔΔCt method, as summarised by
Livak and Schmittgen [113], was used to compare mRNA
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negative controls. Primer/probe pairs were used to meas-
ure the expression of SOX2 (Hs00602736_s1, Applied Bio-
systems, USA) and an endogenous normalisation control,
GAPDH (4331182, Applied Biosystems, USA). The RNA
samples were used for down-stream gene and miRNA
analysis. Western blot was performed with standard
methods, using the enhanced chemiluminescence devel-
oped previously by Haan and Behrmann [114]. For prob-
ing, primary antibodies were used against SOX2 (ab75485,
AbCam, UK) and the endogenous normalisation control,
GAPDH (ab8245, AbCam, UK).
MicroRNA expression analysis
Whole-miRNAome analsysis was performed with the
TaqMan® Array Human microRNA system (Applied Bio-
systems, USA) as per manufacturer’s protocols. This pro-
vided a high-throughput method to quantitatively screen
the expression of 754 unique miRNAs, covering the
broad majority of human miRNAs in the Sanger miR-
Base v14 miRNA database [44]. For this, cDNA prepared
from the sample RNA underwent qRT-PCR on a pair of
384-well plates containing lyophilised primer/probe pairs.
Three biological replicates were analysed for both func-
tional and negative control samples. To enhance the de-
tection of low-concentration miRNAs, a pre-amplification
step was included using the TaqMan PreAmp Master Mix
with the Megaplex PreAmp Primers (Applied Biosystems,
USA). The manufacturer’s DataAssist 3.0 software was
used to batch-analyse the expression results. MiRNAs that
were deregulated with a P-value of ≤0.05 were included in
the final dataset.
Gene array analysis
The Affymetrix GeneChip Human Gene 1.0 ST array
platform was used to study the differential expression of
28,132 transcripts. RNA integrity was measured with the
2100 Bioanalyzer microfluidics station (Agilent, USA) ac-
cording to manufacturer’s protocols. The preparation
and labelling of sense cDNA was performed to manufac-
turers’ protocols with the WT Expression Kit (Ambion,
USA) and the GeneChip WT Terminal Labeling kit
(Affymetrix, USA). Hybridisation, washing and staining
was performed with Hybridization, Wash and Stain Kit
(Affymetrix, USA). Scanning and quality control analysis
was performed on the GeneChip Scanner 3000 7G (Affy-
metrix, USA) with the manufacturer’s propriety software
using the robust multi-array average analysis. Three bio-
logical replicates were performed with both the func-
tional and negative control samples. Computational
expression analysis was performed using the open-
source R (CRAN) package, Bioconductor 2.9 with the
limma (Linear Models for Microarray Data) add-on
[115]. Gene array results were subsequently validatedwith qRT-PCR. To reduce the chance of false positive
results from downstream analysis, differentially ex-
pressed genes included in the final dataset were those
that were ≥2-fold deregulated with a P-value of ≤0.01
and false discovery rate value of ≤0.05.
Gene and miRNA annotation analysis and network
mapping
To categorise genes by function, we primarily performed
gene ontology analysis using DAVID Bioinformatics Re-
sources 6.7 [49]. On significant findings from DAVID
and on unannotated genes we performed further litera-
ture searches for gene functionality using a defined list
of MeSH terms which included those related to ESCs,
EC cells, CSCs, differentiation, embryonic development,
EMT and cancer. Figure 3C was compiled from miRNA-
target interactions and SOX2 binding sites predicted in
this study. Figure 3C was further enriched with previ-
ously validated transcriptional and post-transcriptional
interactions between miRNAs, EMT genes and SOX2 as
described in Table 2, Table 3 and the text.
Integrated gene and miRNA cross-analysis
To find a functionally enriched set of miRNAs that are
predicted to target the set of significantly deregulated
genes, we adapted a Monte Carlow algorithm previously
successfully used by Stone et al. and Bulik-Sullivan et al.
[47,79]. Briefly, genes with at least one miRNA target
site in TargetScan 6.0 were randomly selected from the
human genome. The number of random genes selected
was equal to the size of each group of upregulated or
downregulated genes in 2102Ep and NTera-2 cells. From
this set the number of genes that each human miRNA in
the TargetScan 6.0 database was predicted to target was
calculated. From this a weighted score was calculated
based on the number of predicted target site per 3′UTR,
the distance between target sites and the type of pre-
dicted hybridisation. This simulation was repeated
10,000 times to calculate a background distribution of
the number of genes each human miRNA is predicted to
target. This distribution was subsequently used to calcu-
late an empirical p-value for the predicted number of
upregulated or downregulated target genes in 2102Ep
and NTera-2 cells. To account for the differences in
average 3′UTR length between these four groups and
their respective groups of randomly selected genes, the
number of predicted target genes was normalised against
the average 3′UTR length of the randomly selected
genes. To establish additional confidence in the prob-
ability of the generated miRNA-target interactions, all
miRNAs were further screened for their targets using
the microT-CDS and miRanda (August 2010 release)
computational target prediction tools [56,57]. For
microT-CDS a threshold of ≥0.4 was set (a ‘medium-
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Randa a mirSVR maximum of ≥0.1 (a ‘good’ setting ac-
cording to the authors) was applied.Supporting data
The data sets supporting the results of this article are in-
cluded within the article and its Supplementary Tables.Additional files
Additional file 1: Table S1. Differentially regulated miRNAs in 2102Ep
and NTera-2 cells. All differentially regulated miRNAs after SOX2 knock-down
in 2102Ep and NTera-2 cells.
Additional file 2: Table S2. MiRNA expression in undifferentiated
NTera-2 cells compared to undifferentiated 2102Ep cells. All differentially
regulated miRNAs between the two hECC cell lines in their undifferentiated,
unaltered state.
Additional file 3: Table S3. Genes deregulated in 2102Ep and NTera-2
cells after SOX2 knock-down. All genes differentially regulated in 2102Ep
and NTera-2 cells three days after SOX2 knock-down. Including a table
with genes deregulated in both cell lines.
Additional file 4: Table S4. DAVID Bioinformatics Resources 6.7 Output
for 2102Ep and 2102Ep cells. Gene annotation analysis of all deregulated
genes in 2102Ep and NTera-2 cells by DAVID Bioinformatics Resources 6.7.
Additional file 5: Table S5. Predicted miRNA-target interactions by
master regulator miRNAs. Master regulator miRNAs and their targets as
predicted by our statistical analysis and further enhanced by microT-CDS
and miRanda prediction with prediction scores included.
Additional file 6: Table S6. MiRNAs with proximal SOX2 TFBSs. All
miRNAs with TSSs close to SOX2 TFBSs as defined by the criteria outlined
in the study. The table includes miRNA TSS coordinates and SOX2 TFBS
coordinates.
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